Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than <i>Clostridium difficile</i> infection: a systematic review and meta-analysis
Jessica Green(Barwon Health), Jessica A. Davis(Barwon Health), Michael Berk(Barwon Health), Christopher Hair(Barwon Health), Amy Loughman(Barwon Health), David Castle(The University of Melbourne), Eugene Athan(Barwon Health), Andrew A. Nierenberg(Harvard University), John F. Cryan(University College Cork), Felice N. Jacka(Barwon Health), Wolfgang Marx(Barwon Health)
Cited by 150Open Access
Abstract
= .739). Hepatic disorders, metabolic syndrome, and antibiotic-resistant organisms were conditions with emerging data on FMT. Serious adverse events (AE) were more often reported in control group participants (n = 43) compared with FMT group participants (n = 26). There were similar rates of mild to moderate AE in both groups. Preliminary data suggest that FMT is a potentially safe, well-tolerated and efficacious treatment for certain conditions other than CDI, with evidence for active UC being the most compelling.
Related Papers
No related papers found
Powered by citation graph analysis